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Abstract
Backgrounds: We conducted a pilot study of the infusion of intravenous autologous cord blood (CB) in children
with cerebral palsy (CP) to assess the safety and feasibility of the procedure as well as its potential efficacy in
countering neurological impairment.
Methods: Patients diagnosed with CP were enrolled in this study if their parents had elected to bank their CB at
birth. Cryopreserved CB units were thawed and infused intravenously over 10~20 minutes. We assessed potential
efficacy over 6 months by brain magnetic resonance imaging (MRI)-diffusion tensor imaging (DTI), brain perfusion
single-photon emission computed tomography (SPECT), and various evaluation tools for motor and cognitive
functions.
Results: Twenty patients received autologous CB infusion and were evaluated. The types of CP were as follows: 11
quadriplegics, 6 hemiplegics, and 3 diplegics. Infusion was generally well-tolerated, although 5 patients
experienced temporary nausea, hemoglobinuria, or urticaria during intravenous infusion. Diverse neurological
domains improved in 5 patients (25%) as assessed with developmental evaluation tools as well as by fractional
anisotropy values in brain MRI-DTI. The neurologic improvement occurred significantly in patients with diplegia or
hemiplegia rather than quadriplegia.
Conclusions: Autologous CB infusion is safe and feasible, and has yielded potential benefits in children with CP.
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Backgrounds
Cord blood (CB) was introduced for the first time in
humans to reconstitute the hematopoietic system in
patient with Fanconi anemia [1]. Since the first cord
blood transplantation (CBT), more than 20,000 CBTs
have been reported worldwide and more than 400,000
CB units have been stored in more than 100 CB banks
[2]. The clinical use of CB has expanded into various
areas such as inherited metabolic disorders. CBT for
Hurler syndrome resulted in either stabilization or
improvement of neurocognitive function, and mainte-
nance of new skills [3]. CBT for infantile Krabbe disease
was highly effective if patients received transplants early
i nt h ec o u r s eo ft h ed i s e a s e[ 4 ] .I ns u c hp a t i e n t s ,C B T
can prevent demyelination in the central and, often, the
peripheral nervous system, extending life and improving
overall quality of life. Kurtzberg, et al found that donor
cells could enter the brain and induce remyelination
and improvement in neurologic function in demyelinat-
ing diseases.
Cerebral palsy (CP) describes a group of permanent
disorders of movement and posture limiting activity, due
to non-progressive disturbances that occurred in the
developing fetal or infant brain [5]. The ultimate goal of
any therapy program for CP is to help children achieve
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social realms. Despite a wide range of medical and surgi-
cal interventions in children with CP, and at risk of CP,
there is no cure and significant variability in outcome, in
part due to the heterogeneous nature of the underlying
brain pathology.
Recently, the clinical application of CB in regenerative
medicine has expanded using mesenchymal stem cells
(MSC) and mononuclear cells (MNC). Since CB contains
hematopoietic stem cells as well as a mixture of multipo-
tent stem cells, such as unrestricted somatic stem cells,
mesenchymal stem cells, and endothelial colony-forming
cells, CB has the ability to regenerate numerous tissue
types and improve their function. The evidence that CB
cells express neurotrophic factors and produce cytokines
that may be partially responsible for the functional brain
repair, has prompted investigation of the therapeutic use
of CB in various neurologic diseases [6,7]. MSC and MNC
have been administered intrathecally and intravenously in
experimental and clinical trials for neurologic disorders
[8-11]. However, there is no definitive evidence concerning
the optimum route for cell therapy. Intravenous infusion
of autologous CB MNC in children with CP represents a
novel and safe challenge that may involve a quite different
mechanism of action from previous treatment methods.
We have conducted a single arm pilot study of intra-
venous autologous CB MNC infusion in children with
CP to assess the safety and feasibility of the procedure
as well as any effect in improving neurological function.
Methods
Patients
The study was approved by our institutional research
ethics committee, and written informed parental consent
was obtained for all patients. Twenty young patients aged
2~10 years and diagnosed with CP due to various causes
were enrolled since their parents had elected to bank their
CB privately (Medipost Biomedical Research Institutes,
Seoul, Korea) at birth; patients with epilepsy were
excluded. The participants were not provided with any
additional medication or rehabilitation programs and for
ethical reasons there was no control group. The diagnoses
of CP were based on history taking, routine laboratory
tests, genetic and metabolic studies, chromosome analysis,
and neurological examination. To confirm the diagnoses,
2 clinicians, a pediatrician and a physiatrist, examined the
patients. The major signs that collectively led to the diag-
nosis of CP were delayed motor milestones, abnormal
neurologic examination, persistence of primitive reflexes,
and abnormal postural reactions.
Study protocol
Cryopreserved CB was delivered from the CB bank and
infused intravenously over 10~20 minutes after thawing
at the bedside, followed by administration of hydration
fluid for 4~6 hours. To assess the short-term safety of
CB infusion, we monitored vital signs and checked for
symptoms such as fever, chills, nausea, and vomiting
t h a tc o u l db ec a u s e db yt o x i c i t yo ft h ec r y o p r o t e c t a n t
and/or by lysis of red blood cells upon thawing the CB.
The whole volume of thawed CB was infused and its
cellular content then analyzed to enable evaluation of
the impact of cell dose on clinical improvement. To
assess the long-term safety of CB infusion and to mea-
sure neurodevelopmental changes, all the CP patients
were followed up in the departments of pediatrics and
rehabilitation medicine on the 4th, 8th, 12th, 24th
weeks after infusion of CB.
The neurodevelopmental tests were carried out each
time along with measurements of vital signs, weight and
height, in addition to a complete blood cell count, uri-
nalysis, and blood chemistry. Comparative analyses of
brain perfusion single-photon emission computed tomo-
graphy (SPECT), and magnetic resonance imaging
(MRI) with diffusion tensor imaging (DTI), were per-
formed at 24 weeks after infusion of CB.
Neurodevelopmental examinations
Before and after the infusion of CB, all the CP patients
were assessed by comprehensive neurodevelopmental
examinations including the Denver development screen-
ing test II (DDST- II) as a gross developmental screening,
the pediatric evaluation of disability inventory (PEDI) as
a detailed developmental assessment, the gross motor
function classification system (GMFCS) for gross motor
function staging, the gross motor function measure-88
(GMFM) as a detailed motor function test, the manual
ability classification system (MACS) for fine motor sta-
ging, and the quality of upper extremity skill test
(QUEST) for fine motor function testing. The results for
each examination tool were evaluated by well-trained
physical and occupational therapists, and therapeutic
responses were comprehensively assessed by rehabilita-
tion specialists.
Imaging studies
Brain perfusion SPECT, and conventional brain MRI-DTI
were performed to evaluate functional changes of the
brain. Fractional anisotropy (FA) values were obtained
from the DTI data for 26 regions of interest (ROIs). All
ROIs were set by the two pediatric neurologists, and all
measurements were performed twice, and mean values
used for analysis. We compared pre- and post-treatment
FA values in the same patient. We also evaluated the cor-
relation of FA value changes with neurodevelopmental
changes. Brain perfusion SPECT using Tc-99 m ethyl
cysteinate dimer was performed as a baseline study and
as a follow-up study 24 weeks after infusion of CB. Brain
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Page 2 of 11perfusion SPECT images were evaluated visually by a
nuclear medicine physician, and by semiquantitative ana-
lysis using an asymmetry index calculated as the relative
uptake ratios in ROIs drawn in the frontal, temporal, par-
ietal, and occipital cortices, basal ganglia and thalamus of
both hemispheres.
Statistical Analysis
In the analysis of FA values, a weighted kappa analysis
was performed to measure inter-rater agreement. The
Wilcoxon signed-rank test was used to compare differ-
ences of FA values pre- and post-treatment. In the com-
parative analysis of global outcome in the clinical
characteristics and infused total nucleated cell (TNC)
counts at 24 weeks after infusion, the variables were
compared using Fisher’s exact test and Wilcoxon rank-
sum test. P values of ≤ 0.05 were considered significant.
All statistical analyses were performed with SPSS (ver-
s i o n1 5 . 0 ,S P S SI n c ,C h i c a g o ,I L ,U S A )s t a t i s t i c a l
software.
Results
Twenty patients (8 male, 12 female) received autologous
CB infusion and were evaluated. Mean age and body
weight at infusion were 55 (23~91) months and 13.9
(7.2~21.4)kg, respectively. Possible causes of the CP
were: 8 hypoxic ischemic encephalopathies, 1 strepto-
coccal meningitis, 1 middle cerebral artery infarction,
1 polymicrogyria, and 9 unknown. Types of CP were: 11
quadriplegia, 6 hemiplegia, 3 diplegia.
TNC of 5.5 ± 3.8 (0.6~15.65) × 10
7/kg were infused.
The viability of the cells before freezing was 95.4 ±
3.5%; it was not measured after thawing. Infusion was
generally well-tolerated, even without premedication,
although 3 patients experienced temporary nausea and
hemoglobinuria, and another 2 patients experienced
hemoglobinuria and urticaria, respectively, but these
were easily controlled with peniramine or intravenous
hydration. Although 14 of the 20 patients had increased
scores in at least one of the 4 neurodevelopmental tests
after CB infusion, only 5 patients (4 hemiplegia, 1 diple-
gia) showed more improvement in the neurodevelop-
mental tests than would normally be expected over a 6
month period. The neurodevelopmental improvements
occurred significantly in patients with hemiplegia or
diplegia rather than with quadriplegia (p = 0.008). Other
variables, such as sex, age, body weight, infused TNC
counts as well as possible causes of CP did not show
any significant differences in global outcomes. Overall
therapeutic responses according to clinical characteris-
tics and infused TNC counts of CP patients are shown
in Table 1.
In the analysis of FA values in MRI-DTI, significant
differences between pre-treatment and post-treatment
values were found in only 3 ROIs (right temporal, cor-
pus callosum, and right periventricular white matter)
out of 26. In the 5 patients who showed comprehensive
improvements in the neurodevelopmental tests, we
examined these areas to analyze the clinical significance
of the FA value changes. The differences of white matter
integrity (FA values) in ROIs of 5 patients who showed
clinical improvement after autologous CB infusion are
presented in Table 2.
In the brain perfusion SPECT analysis, 2 (UPN 8,9) of
the patients who experienced clinical improvement dis-
played improved perfusion. Both had mild forms of hemi-
plegia, and reduced perfusion in the left thalamus in the
baseline SPECT studies, which increased in the SPECT
images at 24 weeks. Six patients (UPN 6,12,13,14,15,16)
showed decreased perfusion in the unilateral thalamus in
the baseline SPECT images, and this expanded to the con-
tralateral thalamus in the subsequent SPECT images. The
rest of the patients (n = 12) showed no significant changes
in cerebral perfusion state in SPECT images.
The detailed changes in the 5 patients in whom we
detected neurological improvement after CB infusion
are set out below.
UPN 8 (F/71 months old)
This child had functional hemiplegia and polymicro-
gyria on conventional brain MRI. One month after CB
infusion, she improved on the personal-social, fine
motor-adaptive, and language scales of DDST-II. She
became able to dress herself and brush her teeth on the
personal-social scale of DDST-II. Her score on the fine
motor adaptive scale increased markedly in three
m o n t h s .S h ec o u l dm a k ep i l e so f6t o8b l o c k s ,a n dw a s
able to draw straight lines and circles. In GMFM, her
balance while standing was enhanced as was her ability
to jump over sticks and stand on one foot. In terms of
PEDI-functional skills, she showed increased mobility
and a slight improvement in social function. She also
had slightly increased self-care, mobility, and social
function in terms of problem solving, self-awareness
and time orientation in the PEDI-caregiver assistant
scale (Figure 1). In the analysis of MRI-DTI, we noted
increments of FA values in the right temporal area,
among the three significant areas. She displayed
decreased perfusion in the left thalamus and right basal
ganglia in the baseline SPECT study, and improved
perfusion in these areas in subsequent brain perfusion
SPECT images (Figure 2).
UPN 9 (M/43 months old)
This child was a preterm baby with hypoxic-ischemic
encephalopathy, displaying weakness on his left side
with periventricular leukomalacia. Fine motor-adaptive
function such as circle drawing and personal-social
functioning such as independent dressing improved
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months by improvements in brushing teeth and fol-
lowing the rules of games, as well as gross motor func-
tions on the DDST-II scale. Walking, running, and
standing abilities, along with total scores in the
GMFM, increased consistently. In PEDI-functional
skills, mobility, self-care, and social function remained
stationary for 3 months after CB infusion. In PEDI-
caregiver assistance, all factors increased slightly after
2 months (Figure 3). In the analysis of MRI-DTI, we
noted an increment of FA value in the right periventri-
cular white matter. Perfusion in left thalamus was
reduced in the baseline SPECT images, but improved
in subsequent SPECT images.
UPN 11 (F/53 months old)
This little girl was hemiplegic with no defined cause.
Scores on the personal-social scale in DDST-II, in
skills such as brushing teeth with assistance, undres-
sing, using fork and spoon, and tidying toys, increased
dramatically 1 month after CB infusion, and fine
motor-adaptive activities such as tapping an object
with either hand, picking a plum from a bottle and pil-
ing up pairs of blocks began to increase after 2
months. Standing ability in GMFM increased after the
second month, and there was a gradual increase in
functional skills and caregiver assistance in PEDI self-
care activities such as using utensils, grooming, wash-
ing her face and bowel management, and in social
functions including language comprehension and play-
ing with toys (Figure 4). In the analysis of MRI-DTI,
an increment of FA values in the right posterior peri-
ventricular white matter and right periventricular
white matter was noted. Perfusion in the left posterior
frontal and upper temporal cortexes, left basal ganglia,
left thalamus and left cerebellum was reduced in the
baseline SPECT images, and did not change signifi-
cantly in subsequent SPECT images.
UPN 12 (F/40 months old)
This little girl was a preterm baby with hypoxic-
ischemic encephalopathy, and displayed weakness on
her left side with periventricular leukomalacia. All
functions except gross motor function in DDST-II
improved by 2 months after CB infusion. She could
dress herself and follow the rules of games on the per-
sonal-social scale, and was also able to use building
blocks, draw circles, drawing a person and distinguish
two straight lines on the fine motor-adaptive scale.
Language improved markedly after the first month.
She became able to understand the identities of
objects, prepositions and adjectives on the language
Table 1 Therapeutic responses to autologous cord blood infusion according to clinical characteristics and infused TNC
counts
UPN Sex Age (Mo) BW (Kg) TNC (10^7/kg) Dx Tx Response
Type GA Possible Causes DDST II PEDI GMFCS MACS Overall
1 M 80 13 5.38 Quad Full Unknown N Y N N N
2 F 24 10 6.72 Quad Full HIE, PVL N N Y N N
3 F 91 14 10.92 Quad Full Unknown N Y N N N
4 F 91 19.5 2.87 Quad Full HIE, MAS N N N N N
5 F 82 18.1 4.36 Di Full Unknown N Y N N N
6 F 28 7.2 9.58 Quad Full Unknown N N N N N
7 M 31 11.2 5.72 Quad Full Strep meningitis N N N N N
8 F 71 21.4 2.89 Hemi Full Polymicrogyria Y Y N N Y
9 M 43 16.4 0.6 Hemi Preterm HIE, PVL Y Y N Y Y
10 F 75 9.4 10.63 Quad Full HIE, MAS N N N N N
11 F 53 15.3 5.88 Hemi Full Unknown N Y N N Y
12 F 40 12.7 2.44 Hemi Preterm HIE, PVL N Y N Y Y
13 M 29 10.8 6.85 Di Preterm HIE, PVL Y Y N N Y
14 M 67 15 5.26 Quad Full Unknown N N N N N
15 M 78 20 5.14 Hemi Full HIE, ICH, Infarction Y Y N N N
16 F 71 17.9 2.86 Di Full Unknown N Y N N N
17 F 58 11.6 15.65 Quad Preterm HIE, PVL N Y N N N
18 M 29 11.3 0.71 Quad Full Unknown N Y N N N
19 F 30 11.5 3.29 Hemi Full MCA infarction N N N N N
20 M 23 10.9 2.25 Quad Full Unknown N Y N N N
UPN; unique patient number, BW; body weight, TNC; total nucleated cells, Dx; diagnosis, Tx; treatment, GA; gestational age, DDST-II; Denver developmental
screening test II, PEDI; pediatric evaluation of disability inventory, GMFCS; Gross motor function classification system, MACS; Manual ability classification system,
Quad; quadriplegic, Di; diplegic, Hemi; hemiplegic, Full; full-term, HIE; hypoxic ischemic encephalopathy, PVL; periventricular leukomalacia, MAS; meconium
aspiration pneumonia, Strep; streptococcal, ICH; intracranial hemorrhage, MCA; middle cerebral artery, N; no, Y; yes
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GMFM, and all tests showed a gradual increase in
PEDI-functional skills. Self-care, mobility, and social
function increased dramatically on the PEDI-caregiver
assistance scale (Figure 5). In the analysis of MRI-DTI,
increments of FA values in the right temporal and cor-
pus callosum were noted. There was decreased perfu-
sion in the bilateral anterior medial frontal cortex, and
a suspicion of decreased perfusion in the bilateral tha-
lamus on the baseline SPECT images, and this was fol-
lowed by a definite decrease of perfusion in the
bilateral thalamus on subsequent SPECT images.
UPN 13 (M/29 months old)
This male child was diplegic and preterm with peri-
ventricular leukomalacia. One month after CB infu-
sion language improved, and fine motor-adaptive
functions followed after the second month. After the
third month, personal-social skills including ability
to undress, dress, brush teeth with help, put on a
shirt and say the names of friends improved in
DDST-II. In GMFM, standing improved dramati-
cally, along with improvements in crawling and
kneeling, as well as walking and running, after the
third month. He was able to attempt to stand on
alternate feet. In PEDI, all scales increased gradually.
Improvements were achieved in using utensils, main-
taining self-hygiene, bathing, bowel and bladder
management, and problem-solving ability and time-
orientation also improved (Figure 6). In the analysis
of MRI-DTI, an increment of FA values in the right
temporal area was noted. There was reduced perfu-
sion in the right thalamus in the baseline SPECT
Table 2 Differences of white matter integrity (FA values) of the 5 patients who showed neurodevelopmental
improvement
ROIs UPN 8 UPN 9 UPN 11 UPN 12 UPN 13
Pre Post Pre Post Pre Post Pre Post Pre Post
Temporal TR * 0.431 0.451 0.438 0.421 0.425 0.445 0.463 0.464 0.416 0.430
TL 0.483 0.457 0.448 0.456 0.319 0.346 0.460 0.444 0.423 0.460
Orbito-frontal FR 0.411 0.465 0.470 0.378 0.359 0.386 0.421 0.438 0.466 0.728
FL 0.469 0.490 0.450 0.383 0.319 0.336 0.423 0.438 0.462 0.450
Inferior frontal IFR 0.453 0.446 0.444 0.447 0.397 0.370 0.404 0.437 0.443 0.474
IFL 0.506 0.515 0.494 0.383 0.320 0.334 0.457 0.464 0.452 0.454
Internal capsule ICR 0.489 0.499 0.498 0.570 0.501 0.534 0.476 0.498 0.467 0.465
ICL 0.527 0.520 0.493 0.504 0.336 0.328 0.496 0.496 0.478 0.454
CC * 0.534 0.538 0.493 0.487 0.421 0.427 0.443 0.509 0.481 0.447
S 0.502 0.536 0.472 0.495 0.421 0.421 0.512 0.549 0.471 0.465
Periventricular white matter AWMR 0.374 0.366 0.363 0.300 0.363 0.369 0.363 0.307 0.373 0.332
AWML 0.423 0.385 0.375 0.315 0.264 0.228 0.349 0.371 0.332 0.378
PWMR* 0.479 0.479 0.400 0.425 0.426 0.481 0.407 0.415 0.398 0.408
PWML 0.488 0.484 0.476 0.442 0.314 0.392 0.459 0.444 0.414 0.410
Occipital OR 0.443 0.457 0.523 0.449 0.441 0.446 0.450 0.430 0.414 0.434
OL 0.483 0.510 0.488 0.395 0.284 0.271 0.536 0.509 0.441 0.391
Sup frontal subcortex SFR 0.475 0.447 0.484 0.444 0.346 0.330 0.345 0.431 0.452 0.433
SFL 0.455 0.460 0.443 0.360 0.308 0.334 0.399 0.401 0.452 0.440
Middle frontal paravent WM MFPAR 0.336 0.319 0.363 0.379 0.389 0.396 0.378 0.381 0.389 0.414
MFPAL 0.455 0.447 0.433 0.389 0.263 0.237 0.385 0.387 0.387 0.438
Parietal perivent WM PPER 0.468 0.451 0.447 0.440 0.466 0.504 0.446 0.479 0.435 0.445
PPEL 0.519 0.514 0.458 0.456 0.342 0.350 0.453 0.458 0.446 0.453
Post parietal perivent WM PPPER 0.467 0.507 0.405 0.467 0.477 0.495 0.492 0.488 0.391 0.476
PPPEL 0.465 0.466 0.464 0.427 0.284 0.284 0.452 0.525 0.408 0.372
Post parietal paravent WM PPPAR 0.445 0.497 0.336 0.412 0.480 0.477 0.433 0.473 0.425 0.508
PPPAL 0.441 0.443 0.381 0.359 0.273 0.288 0.448 0.422 0.374 0.425
UPN; unique patient number, TR; right temporal, TL; left temporal, FR; right orbito-frontal, FL; left orbito-frontal, IFR; right inferior frontal, IFL; left inferior frontal,
ICR; right internal capsule, ICL; left internal capsule, CC; corpus callosum, S; splenium, AWMR; right anterior periventricular white matter, AWML; left anterior
periventricular white matter, PWMR; right posterior periventricular white matter, PWML; left posterior periventricular white matter, OR; right occipital, OL; left
occipital, SFR; right superior frontal subcortex, SFL; left superior frontal subcortex, MFPAR; right anterior middle frontal paraventricular white matter, MFPAL; left
anterior middle frontal paraventricular white matter, PPER; right parietal periventricular white matter, PPEL; left parietal periventricular white matter, PPPER; right
posterior parietal periventricular white matter, PPPEL; left posterior parietal periventricular white matter, PPPAR; right posterior parietal paraventricular white
matter, PPPAL; left posterior parietal paraventricular white matter (* indicates the ROIs demonstrated significant differences between pre-treatment and post-
treatment values out of 26 ROIs.)
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Page 5 of 11Figure 1 Neurodevelopmental evaluation in UPN 8. One month after cord blood infusion, personal-social, fine motor-adaptive, and language
scores in DDST-II improved. In GMFM, most domains improved gradually, while in PEDI, social function improved slightly. DDST-II; Denver
developmental screening test II, PEDI; pediatric evaluation of disability inventory, GMFM; Gross motor function measure-88.
Figure 2 Brain perfusion SPECT analysis. The low perfusion in the left thalamus in the baseline study (white arrow, upper lane), has been
corrected in subsequent images at 24 weeks (white arrow, lower lane) after infusion of cord blood.
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Page 6 of 11Figure 3 Neurodevelopmental evaluation of UPN 9. Fine motor-adaptive and personal-social function in DDST-II improved after 3 months.
Walking, running, and total functional scores increased in GMFM. All factors in PEDI-caregiver assistance slightly improved. DDST-II; Denver
developmental screening test II, PEDI; pediatric evaluation of disability inventory, GMFM; gross motor function measure-88.
Figure 4 Neurodevelopmental evaluation of UPN 11. In DDST-II, the personal-social score increased dramatically by 1 month after infusion
and fine motor-adaptive function also increased by 3 months after infusion. In PEDI, self-care and social function gradually increased. DDST-II;
Denver developmental screening test II, PEDI; pediatric evaluation of disability inventory, GMFM; gross motor function measure-88.
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Page 7 of 11image, and perfusion worsened in the bilateral thala-
mus in the subsequent SPECT images.
Discussion
We observed that 25% of children with CP showed partial
improvements in neurodevelopmental evaluation tests fol-
lowing intravenous, autologous CB MNC infusion. Inter-
estingly, neurologic improvement was seen in patients
with diplegia or hemiplegia rather than with quadriplegia,
although this study is limited by the small number of sub-
j e c t sa sw e l la st h ed i f f e r e n tt y p e so fC Pa n du n d e r l y i n g
causes. Brain plasticity is another limitation of this trial.
However, we attempted to reduce any confounding effects
of brain plasticity by including only patients between 2
and 10 years of age, to minimize the effect of brain plasti-
city during the first few years of life, and at the same time
to maximize the kilogram-based cell dose of infused CB.
We also demonstrated that age did not significantly affect
global outcomes.
Abnormalities are demonstrable in many children with
CP by conventional MRI, and DTI can be used to visua-
lize brain white matter tracts, and has been shown to
improve the detection of lesions in a range of neurologic
d i s o r d e r s[ 1 2 ] .T r i v e d i ,e ta ld emonstrated a correlation
between clinical grade and DTI measurements in motor
and sensory pathways in children with CP [13]. Yoshida,
et al demonstrated that ROI-based FA values in the corti-
cospinal tract and posterior thalamic radiation were sig-
nificantly lower in children with CP than in control
children, and they suggested that the DTI parameters of
corticospinal tract and posterior thalamic radiation are
useful variables for evaluating clinical motor status and
outcomes in children with CP [14]. Hoon, et al also
showed a significant correlation between DTI scores in
thalamocortical pathways and the quantitative clinical
status of children with CP [15]. We also analyzed MRI-
DTI data to obtain imaging evidence of neurologic
improvements. Based on findings from the aforemen-
tioned studies, we chose 24 weeks after CB infusion as
the time for this analysis. Because we did not use control
MRI-DTI data from healthy volunteers, we attempted to
identify ROIs in which there were significant differences
of FA values between pre- and post-treatment. We found
that FA values in only 3 of the total of 26 ROIs displayed
significant differences between pre- and post-treatment
in the 19 evaluable patients. We assessed the correlation
between clinical changes and changes in FA values in
these 3 ROIs, in the 5 patients who showed neurodeve-
lopmental improvements. The improved language scale
and self awareness in UPN 8 may have been related to
Figure 5 Neurodevelopmental evaluation of UPN 12. All functions except gross motor in DDST-II improved by 2 months after infusion.
Walking and running steadily improved in GMFM. Self-care, mobility, and social functions increased gradually on PEDI-caregiver assistance scale.
DDST-II; Denver developmental screening test II, PEDI; pediatric evaluation of disability inventory, GMFM; gross motor function measure-88.
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Page 8 of 11the increased FA values in the temporal lobe, but this lat-
ter cannot fully explain the overall improvements in the
fine motor and social areas. FA values in the right peri-
ventricular white matter area increased in UPN 9 and
could underlie his improvement in GMFM and fine
motor-adaptive function. In UPN 11, the MRI-DTI
changes involving partial increases in the anisotropy of
the temporal lobe and posterior thalamic radiation could
be related to her improved language function and
increased score in mobility and self care ability. FA values
in the corpus callosum increased in UPN 12; the corpus
callosum is a highly dense pathway of white matter con-
necting right and left hemispheres, and the increase of
FA after treatment could indicate improvement in the
connectivity of the corpus callosum that permitted more
effective transfer of information between the two sides of
the brain. In UPN 13, the increase in FA values in the
right temporal area might explain the improved function-
ing of the language area, but does not account for the
increased fine motor function, mobility and other overall
improvements.
In the brain perfusion SPECT analysis, 2 of the patients
who showed clinical improvement displayed improved
perfusion in thalamic areas, while regions of decreased
perfusion, mainly in thalamic areas, expanded in another
6 patients. However, small, deep-seated structures such
as the thalamus are susceptible to artifacts in SPECT
images caused by attenuation of the low energy gamma
rays emitted by these structures. Decreased image activity
can be caused by increased attenuation, so that subtle
changes can be artifactual. Further studies using brain
positron emission tomography images generated by
higher energy gamma rays could provide more reliable
data on small, deep-seated structures.
Most studies of tissue regeneration have been per-
formed by injecting MSC into target organ, although a
variety of stem cell sources and routes of administration
have been used in both animal models and humans. A
double-blind, randomized, controlled trial revealed that
b o n em a r r o w - d e r i v e dM S Cm a yb em o r ee f f e c t i v et h a n
bone marrow-derived MNC in increasing lower limb
perfusion and promoting foot ulcer healing in diabetic
patients [16]. However, intravenously injected MNC
obtained from the bone marrow of rats also induced
functional recovery and decreased neurodegeneration
after sensorimotor cortical ischemia in rats [17]. Reich,
et al also showed that heterogeneous MNC and even
CD133-depleted fractions have the ability not only to
reduce apoptosis in neuronal cells but also to induce the
maintenance of neuronal phenotypes [18].
Figure 6 Neurodevelopmental evaluation of UPN 13. By 1 month after cord blood infusion, language had improved, and in DDST-II there
were step-wise increments in fine motor-adaptive functions and personal-social skills in the following months. In GMFM, standing definitely
improved after the third month. In PEDI, all scores increased gradually. DDST-II; Denver developmental screening test II, PEDI; pediatric evaluation
of disability inventory, GMFM; Gross motor function measure-88.
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for treating injuries, diseases, and neurodegeneration are
becoming increasingly recognized. The mechanisms
underlying functional recovery remain to be clarified.
Although Chen, et al observed that intravenously admi-
nistered CB cells entered the brain, survived, migrated,
and improved functional recovery after stroke [9], few
CB cells are present in ischemic region compared to the
number that were infused [19,20]. The small number of
neural cells derived from the CB cells appears unable to
explain the significant improvement resulting from cell
transplantation. Kurtzberg observed neurological
improvements in children with inborn errors of metabo-
lism following intravenous infusion of CB in allogeneic
CBTs, and detected the transplanted donor cells in reci-
pients’ brains [4]. Based on these experiences, she exam-
ined the effect of autologous CB infusion on neurological
function in children with CP and again observed func-
tional improvements [21].
However, in contrast to conventional hematopoietic
stem cell transplantation with CB, non-hematopoietic
applications such as cardiovascular or neurological indi-
cations do not require permanent graft survival because
the therapeutic activities of the CB are believed to be
mediated in many cases by growth factor secretion
[22,23]. Fan, et al found significantly higher levels of
brain-derived neurotrophic factors (BDNF) and neuro-
trophin-4/5 in the culture supernatants of CB MNC
than of peripheral blood MNC [6].
The neurologic improvement we observed in our study
may be due to some migration of MNC into the brain and
the consequent cellular effects as well as above-mentioned
neurotrophic effects of the CB. Intravenously administered
CB cells would not enter the brain in CP patients without
some challenge such as chemo-radiotherapy which could
induce permeability changes in the blood brain barrier
(BBB). Most studies of intravenous infusion of MNC to
restore neurologic function have been performed in acute
stages of neurological impairment when the BBB is usually
disrupted. However, since Newman, et al have demon-
strated that interleukin (IL)-8, monocyte chemotactic pro-
tein (MCP)-1, and IL-1a are consistently expressed by CB
MNC regardless of culture conditions [7], the cytokines in
CB which have been cited as pro-inflammatory mediators
may be able to affect endothelial cells in such a way as to
cause alterations in tight junction structure, the BBB, and
leukocyte migration [24]. Microglia, which differentiate
from monocytes, are major players in neurogenesis [25].
In inflammatory conditions, there can be both intrinsic
proliferation of parenchymal microglia and substantial
recruitment of monocytes [26]. Although studies have
shown that inflammation and microglial activation can be
detrimental to adult neurogenesis, their effects have
turned out to be more complex and there is recent
experimental evidence that they can be beneficial under
some circumstances and support various steps in adult
neurogenesis. It is conceivable that the early detrimental
effects of microglia after acute injury can in some situa-
t i o n sb ec o n v e r t e di n t oas u p p o r t i v er o l ed u r i n gt h e
chronic phase [27]. Microglia could then release neuro-
trophic factors such as BDNF and glial cell line-derived
neurotrophic factor (GDNF), remove synapses from
damaged neurons and influence the synaptic connectivity
of newly-formed neurons [28].
Conclusion
Autologous intravenous CB MNC infusion seems to be
practicable and safe and has yielded potential benefits in
children with CP. Further clinical studies including rando-
mized, cross-over, long-term follow-up trials, as well as
basic research into the underlying mechanisms, are needed.
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